Si esto es clnicamente significativo en la mayora de los pacientes deber determinarse con datos de resultados cardiovasculares a largo plazo
Research on Specific GI Symptoms Recent research sheds light on how GLP-1 receptor activation triggers distinct gastrointestinal symptoms
The shift went deeper than the mirror
Mice were randomly assigned to control, 2.0% DSS (model), 2.0% DSS+SAPA (200 mg/kg, positive control), 2.0% DSS + SAC high dose (SAC, 200 g/kg) and 2.0% DSS + SAC low dose (SAC-L, 100 g/kg) groups
A BMI of 35 or more with an obesity-related condition or a BMI of 40 or more with no obesity-related condition
During the Super Bowl, telehealth platform Hims & Hers released a controversial ad calling out drugmakers that provide weight loss drugs priced for profits, not patients. It then proceeded to highlight its compounded GLP-1 offerings, calling them affordable, doctor-trusted and formulated in the USA. Shortly after, Novo Nordisk responded to the ad with its own Check before you inject campaign, highlighting the argument that patients should be wary of compounded GLP-1s given that they arent FDA-approved products
